Day One Biopharmaceuticals (NASDAQ:DAWN) PT Raised to $33.00 at Needham & Company LLC

Day One Biopharmaceuticals (NASDAQ:DAWNFree Report) had its price target boosted by Needham & Company LLC from $30.00 to $33.00 in a report released on Wednesday, Marketbeat reports. Needham & Company LLC currently has a buy rating on the stock.

DAWN has been the topic of several other reports. The Goldman Sachs Group dropped their target price on Day One Biopharmaceuticals from $50.00 to $44.00 and set a buy rating on the stock in a research report on Tuesday, February 27th. Oppenheimer reaffirmed a market perform rating on shares of Day One Biopharmaceuticals in a research note on Tuesday, February 27th. JPMorgan Chase & Co. raised their price objective on Day One Biopharmaceuticals from $32.00 to $36.00 and gave the stock an overweight rating in a research note on Monday. Finally, Piper Sandler reaffirmed an overweight rating and issued a $40.00 price objective on shares of Day One Biopharmaceuticals in a research note on Tuesday, March 26th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of Moderate Buy and an average target price of $39.33.

Read Our Latest Report on Day One Biopharmaceuticals

Day One Biopharmaceuticals Price Performance

Shares of NASDAQ:DAWN opened at $15.19 on Wednesday. The stock’s 50-day simple moving average is $15.28 and its two-hundred day simple moving average is $13.79. Day One Biopharmaceuticals has a 52-week low of $9.67 and a 52-week high of $17.85.

Day One Biopharmaceuticals (NASDAQ:DAWNGet Free Report) last announced its earnings results on Monday, February 26th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.57) by ($0.07). Equities analysts anticipate that Day One Biopharmaceuticals will post -2.66 earnings per share for the current year.

Insider Activity at Day One Biopharmaceuticals

In related news, General Counsel Adam Dubow sold 3,242 shares of Day One Biopharmaceuticals stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $15.25, for a total transaction of $49,440.50. Following the sale, the general counsel now owns 16,585 shares of the company’s stock, valued at approximately $252,921.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Day One Biopharmaceuticals news, General Counsel Adam Dubow sold 3,242 shares of Day One Biopharmaceuticals stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $15.25, for a total value of $49,440.50. Following the sale, the general counsel now owns 16,585 shares of the company’s stock, valued at approximately $252,921.25. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Samuel C. Blackman sold 2,258 shares of Day One Biopharmaceuticals stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $15.25, for a total value of $34,434.50. Following the completion of the sale, the insider now directly owns 1,244,662 shares in the company, valued at approximately $18,981,095.50. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 55,781 shares of company stock valued at $883,160. 8.40% of the stock is owned by company insiders.

Institutional Trading of Day One Biopharmaceuticals

A number of large investors have recently added to or reduced their stakes in DAWN. China Universal Asset Management Co. Ltd. increased its stake in Day One Biopharmaceuticals by 130.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 2,226 shares of the company’s stock worth $27,000 after acquiring an additional 1,262 shares during the last quarter. Quest Partners LLC bought a new stake in Day One Biopharmaceuticals in the 4th quarter worth approximately $29,000. Quintet Private Bank Europe S.A. increased its stake in Day One Biopharmaceuticals by 43.2% in the 4th quarter. Quintet Private Bank Europe S.A. now owns 3,313 shares of the company’s stock worth $48,000 after acquiring an additional 1,000 shares during the last quarter. Amalgamated Bank increased its stake in Day One Biopharmaceuticals by 35.7% in the 3rd quarter. Amalgamated Bank now owns 8,628 shares of the company’s stock worth $106,000 after acquiring an additional 2,268 shares during the last quarter. Finally, Exchange Traded Concepts LLC increased its stake in Day One Biopharmaceuticals by 34.0% in the 4th quarter. Exchange Traded Concepts LLC now owns 10,072 shares of the company’s stock worth $147,000 after acquiring an additional 2,554 shares during the last quarter. Institutional investors own 87.95% of the company’s stock.

About Day One Biopharmaceuticals

(Get Free Report)

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.

Recommended Stories

Analyst Recommendations for Day One Biopharmaceuticals (NASDAQ:DAWN)

Receive News & Ratings for Day One Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Day One Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.